FGFR1 and neoplasm: Sulfatinib, a potent oral kinase inhibitor targeting VEGFR (1, 2, 3), FGFR1, and CSF1R with good selectivity, has demonstrated anti-angiogenic and anti-tumor activity in preclinical studies (Hutchison MediPharma, unpublished data).